altretamine (hexalen) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
TRIETHYLENEMELAMINE, an aziridine derivative, is an alkylating agent with antineoplastic properties. Formerly it was used in the palliative treatment of the lymphomas and leukemias. Now it is used as a research tool to produce chromosome aberrations and cancers.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

2,4,6-tris(dimethylamino)-1,3,5-triazine | 2,4,6-tris(dimethylamino)-s-triazine | agn-214868 | altretamin | altretamina | altretamine | altrétamine | altretaminum | hexalen | hexamethylmelamine | hexastat | hexylen | hmm | senrebotase | sxn-100323 | tretamin | tretamine | triamelin | triaziridinyl triazine | triethanomelamine | triethylenemelamine | trisaziridinyltriazine

Organizations (6)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (2)


 

Neoplasms (approved 1954)

Ovarian Neoplasms (approved 1990)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Lymphoma (Phase 1)

Neuralgia, Postherpetic (Phase 2)

Sarcoma (Phase 1)

Urinary Bladder, Overactive (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue